Association Between Nonthyroidal Illness Syndrome and Disseminated Intravascular Coagulation in Sepsis

References

• Rhee C, Dantes R, Epstein L, et al. Incidence and trends of sepsis in us hospitals using clinical vs claims data, 2009–2014. JAMA. 2017;318:1241–1249. doi:10.1001/jama.2017.13836
   PubMed Web of Science ®Google Scholar
• Seymour CW, Gesten F, Prescott HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. New Engl J Med. 2017;376:2235–2244. doi:10.1056/NEJMoa1703058
   PubMed Web of Science ®Google Scholar
• Arina P, Singer M. Pathophysiology of sepsis. Curr Opin Anaesthesiol. 2021;34:77–84. doi:10.1097/ACO.0000000000000963
   PubMed Web of Science ®Google Scholar
• Simmons J, Pittet J-F. The coagulopathy of acute sepsis. Curr Opin Anaesthesiol. 2015;28(2):227–236. doi:10.1097/ACO.0000000000000163
   PubMed Web of Science ®Google Scholar
• Gando S, Shiraishi A, Yamakawa K, et al. Role of disseminated intravascular coagulation in severe sepsis. Thromb Res. 2019;178:182–188. doi:10.1016/j.thromres.2019.04.025
   PubMed Web of Science ®Google Scholar
• Levi M. The coagulant response in sepsis. Clinics Chest Med. 2008;29:627–642. doi:10.1016/j.ccm.2008.06.006
   PubMed Web of Science ®Google Scholar
• Wong HR. Intensive care medicine in 2050: precision medicine. Intensive Care Med. 2017;43:1507–1509. doi:10.1007/s00134-017-4727-y
   PubMed Web of Science ®Google Scholar
• Papathanakos G, Andrianopoulos I, Xenikakis M, et al. Clinical sepsis phenotypes in critically ill patients. Microorganisms. 2023;2023:11.
   Google Scholar
• Zarychanski R, Doucette S, Fergusson D, et al. Early intravenous unfractionated heparin and mortality in septic shock. Crit Care Med. 2008;36:2973–2979. doi:10.1097/CCM.0b013e31818b8c6b
   PubMed Web of Science ®Google Scholar
• Jaimes F, De La Rosa G, Morales C, et al. Unfractioned heparin for treatment of sepsis: a randomized clinical trial (The HETRASE Study). Crit Care Med. 2009;37:1185–1196. doi:10.1097/CCM.0b013e31819c06bc
   PubMed Web of Science ®Google Scholar
• Yamakawa K, Umemura Y, Hayakawa M, et al. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Critical Care. 2016;20:229. doi:10.1186/s13054-016-1415-1
   PubMed Web of Science ®Google Scholar
• Ning N, Li J, Sun W, et al. Different subtypes of nonthyroidal illness syndrome on the prognosis of septic patients: a two-centered retrospective cohort study. Front Endocrinol. 2023;14:1227530. doi:10.3389/fendo.2023.1227530
   PubMed Web of Science ®Google Scholar
• Kim JG, Shin H, Kim W, et al. The value of decreased thyroid hormone for predicting mortality in adult septic patients: a systematic review and meta-analysis. Sci Rep. 2018;8:14137. doi:10.1038/s41598-018-32543-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Sun F, Hong G, et al. Thyroid hormone levels as a predictor marker predict the prognosis of patients with sepsis. Am J Emergency Med. 2021;45:42–47. doi:10.1016/j.ajem.2021.02.014
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801–810. doi:10.1001/jama.2016.0287
   PubMed Web of Science ®Google Scholar
• Taylor FB, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86:1327–1330. doi:10.1055/s-0037-1616068
   PubMed Web of Science ®Google Scholar
• Fliers E, Boelen A. An update on non-thyroidal illness syndrome. J Endocrinol Invest. 2021;44:1597–1607. doi:10.1007/s40618-020-01482-4
   PubMed Web of Science ®Google Scholar
• Bermudez F, Surks MI, Oppenheimer JH. High incidence of decreased serum triiodothyronine concentration in patients with nonthyroidal disease. J Clin Endocrinol Metab. 1975;41:27–40. doi:10.1210/jcem-41-1-27
   PubMed Web of Science ®Google Scholar
• Plikat K, Langgartner J, Buettner R, et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care unit. Metabolism. 2007;56:239–244. doi:10.1016/j.metabol.2006.09.020
   PubMed Web of Science ®Google Scholar
• Gheorghita V, Barbu AE, Gheorghiu ML, et al. Endocrine dysfunction in sepsis: a beneficial or deleterious host response? Germs. 2015;5:17–25. doi:10.11599/germs.2015.1067
   PubMedGoogle Scholar
• Rinaldi I, Sudaryo MK, Prihartono NA, Hebelka H, Lagerstrand KM. Disseminated intravascular coagulation in sepsis and associated factors. J Clin Med. 2022;12:11. doi:10.3390/jcm12010011
   PubMedGoogle Scholar
• Levi M. Disseminated intravascular coagulation in cancer: an update. Semin Thromb Hemost. 2019;45:342–347. doi:10.1055/s-0039-1687890
   PubMed Web of Science ®Google Scholar
• Nogami K, Muraki I, Imano H, et al. Risk of disseminated intravascular coagulation in patients with type 2 diabetes mellitus: retrospective cohort study. BMJ open. 2017;7:e013894.
   PubMed Web of Science ®Google Scholar
• Squizzato A, Romualdi E, Buller HR, et al. Clinical review: thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab. 2007;92:2415–2420. doi:10.1210/jc.2007-0199
   PubMed Web of Science ®Google Scholar
• Gullu S, Sav H, Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Europ J Endocrinol. 2005;152:355–361. doi:10.1530/eje.1.01857
   PubMed Web of Science ®Google Scholar
• Lippi G, Franchini M, Targher G, et al. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. J Thromb Thrombol. 2009;28:362–365. doi:10.1007/s11239-008-0269-z
   PubMed Web of Science ®Google Scholar
• Hayakawa M, Sawamura A, Gando S, et al. A low TAFI activity and insufficient activation of fibrinolysis by both plasmin and neutrophil elastase promote organ dysfunction in disseminated intravascular coagulation associated with sepsis. Thromb Res. 2012;130:906–913. doi:10.1016/j.thromres.2012.01.015
   PubMed Web of Science ®Google Scholar
• Lupoli R, Di Minno MN, Tortora A, et al. Primary and secondary hemostasis in patients with subclinical hypothyroidism: effect of levothyroxine treatment. J Clin Endocrinol Metab. 2015;100:2659–2665. doi:10.1210/jc.2015-1726
   PubMed Web of Science ®Google Scholar
• Akinci B, Comlekci A, Ali Ozcan M, et al. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement. Endocr J. 2007;54:45–52. doi:10.1507/endocrj.K06-062
   PubMed Web of Science ®Google Scholar
• Chapital AD, Hendrick SR, Lloyd L, et al. The effects of triiodothyronine augmentation on antithrombin III levels in sepsis. Am Surg. 2001;67:253–255. doi:10.1177/000313480106700310
   PubMed Web of Science ®Google Scholar
• Vincent JL, Francois B, Zabolotskikh I, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial. JAMA. 2019;321:1993–2002. doi:10.1001/jama.2019.5358
   PubMed Web of Science ®Google Scholar
• Wang C, Chi C, Guo L, et al. Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis. Critical Care. 2014;18:563. doi:10.1186/s13054-014-0563-4
   PubMed Web of Science ®Google Scholar
• Takemitsu T, Wada H, Hatada T, et al. Prospective evaluation of three different diagnostic criteria for disseminated intravascular coagulation. Thromb Haemost. 2011;105:40–44. doi:10.1160/TH10-05-0293
   PubMed Web of Science ®Google Scholar
• Surks MI, Sievert R. Sievert R Drugs and thyroid function. New Engl J Med. 1995;333:1688–1694. doi:10.1056/NEJM199512213332507
   PubMed Web of Science ®Google Scholar